Publication date: Dec 30, 2024
The Chinese government has introduced a series of hierarchical medical policies to ensure continuity of care, but referrals remain difficult to implement effectively. This study aimed to evaluate the chronic disease referral network and explore the problems associated with the specific implementation of referrals. This study was a repeated cross-sectional study of monthly data collected between August 2017 and December 2023 in Luohu district, Shenzhen, China. Social network analysis was used to construct a referral network for chronic disease patients. Density, degree centrality, and betweenness centrality were calculated to assess the relationships and status among different levels of care and their trends. Over seven years, 104,682 chronic disease patients were referred, with a predominance of downward referrals. The number of upward referrals (Z = 2. 5776, P < 0. 01) and downward referrals (Z = 4. 7723, P < 0. 001) increased significantly. Primary care facilities (PCFs) were strongly associated with the tertiary hospital (0. 51-0. 98). The out-degree of all levels of medical institutions showed a significant increasing trend (P < 0. 05). The coronavirus disease 2019 (COVID-19) pandemic did not cause significant level changes in network metrics but accelerated the upward trend in the out-degree of secondary hospitals (P
Open Access PDF
| Concepts | Keywords |
|---|---|
| August | Hierarchical medical system |
| Chinese | Medical consortium |
| December | Network analysis |
| Hospitals | Primary care |
| Pandemic | Referral system |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | chronic disease |
| disease | MESH | coronavirus disease 2019 |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | noncommunicable diseases |
| disease | MESH | premature deaths |
| disease | MESH | acute diseases |
| drug | DRUGBANK | Tretamine |
| disease | IDO | quality |
| drug | DRUGBANK | Serine |
| disease | MESH | hypertension |
| disease | IDO | role |
| disease | MESH | privacy |
| drug | DRUGBANK | Etoperidone |
| disease | MESH | diabetes mellitus |
| disease | MESH | chronic obstructive pulmonary disease |
| disease | IDO | intervention |
| drug | DRUGBANK | Piroxicam |
| drug | DRUGBANK | L-Phenylalanine |
| disease | IDO | process |
| drug | DRUGBANK | Proline |
| disease | MESH | emergencies |
| drug | DRUGBANK | Trestolone |
| disease | MESH | communicable disease |
| disease | MESH | inflammation |
| disease | MESH | uncertainty |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | MESH | stroke |
| disease | MESH | causes |
| disease | MESH | burnout |
| disease | IDO | facility |
| disease | MESH | infection |
| drug | DRUGBANK | Spinosad |
| disease | IDO | healthcare facility |